Choosing between veno-venous (VV) and veno-arterial (VA) extracorporeal membrane oxygenation configurations based on indication and risk profile
The single most important decision in ECMO cannulation is made before a single cannula is placed: does this patient need gas-exchange support alone, or do they also need their circulation carried by the pump? Veno-venous (VV) ECMO oxygenates and decarboxylates blood but leaves cardiac output entirely to the native heart. Veno-arterial (VA) ECMO does both — it can fully replace the pumping function of a failing heart. Getting this triage decision right determines cannulation site selection, expected complications, and weaning strategy for the entire ECMO run.
Every ECMO indication decision reduces to one physiological question: is the problem oxygenation/ventilation, or is it the pump itself?
Isolated respiratory failure (VV-ECMO candidate): • Severe ARDS refractory to lung-protective ventilation (PaO2/FiO2 <80 despite optimized PEEP, prone positioning, neuromuscular blockade) • Status asthmaticus / severe airflow obstruction with refractory hypercapnic acidosis • Bridge to lung transplantation • Primary graft dysfunction after lung transplant • Preserved echocardiographic function, adequate mean arterial pressure on no or low-dose vasopressors
Combined cardiac + respiratory failure, or isolated pump failure (VA-ECMO candidate): • Cardiogenic shock refractory to inotropes/vasopressors (post-cardiotomy, fulminant myocarditis, massive MI) • Refractory cardiac arrest (extracorporeal CPR / ECPR) • Massive pulmonary embolism with right ventricular failure • Sepsis-induced cardiomyopathy with severe biventricular dysfunction • ARDS complicated by acute cor pulmonale / right heart failure severe enough that VV support alone would not sustain perfusion
The assessment is never purely a lab value — it integrates hemodynamics (MAP, lactate, vasopressor requirement), echocardiographic ejection fraction and RV function, and the trajectory of respiratory failure.
A useful mental shortcut: VV-ECMO replaces the lungs; VA-ECMO replaces the heart AND the lungs. If the heart is generating adequate cardiac output and blood pressure on its own, adding arterial return cannulation only adds risk without added benefit.
Several structured scoring tools support (but do not replace) bedside clinical judgment:
Murray Lung Injury Score (respiratory ECMO): • Combines PaO2/FiO2 ratio, PEEP level, static compliance, and chest radiograph quadrants involved • Score ≥3.0, or pH <7.20 with hypercapnia despite maximal conventional management, meets most ELSO (Extracorporeal Life Support Organization) criteria for VV-ECMO consideration
RESP score (Respiratory ECMO Survival Prediction): • Pre-cannulation prognostic score incorporating age, immunocompromised status, duration of mechanical ventilation, and organ dysfunction • Used to counsel families and stratify expected survival (ranges from ~92% in the highest-scoring class to ~18% in the lowest)
Hemodynamic criteria for VA-ECMO: • Cardiac index <2.0–2.2 L/min/m² despite optimal inotropic/vasopressor support • Systolic blood pressure <90 mmHg or MAP <60 mmHg despite adequate volume and inotropes • Serum lactate rising (>4 mmol/L and climbing) reflecting end-organ hypoperfusion • SAVE score (Survival After VA-ECMO): pre-cannulation prognostic tool analogous to RESP score for VA candidates
These tools quantify severity but the decisive branch point remains qualitative: is the myocardium contributing enough to circulation on its own?
ECMO of either configuration is a high-risk, resource-intensive therapy, and indication assessment must also screen for factors that make the risk-benefit ratio unfavorable:
Relative contraindications common to both configurations: • Irreversible underlying disease with no plan for recovery, transplant, or destination device • Severe, unwitnessed prolonged cardiac arrest with poor neurological prognosis • Advanced age with significant comorbidity burden (institution-dependent thresholds) • Active, uncontrolled bleeding, or contraindication to systemic anticoagulation • Multi-organ failure present before cannulation, particularly irreversible
Configuration-specific screening: • VA-ECMO requires patent, cannulatable peripheral (or central) arterial access — severe peripheral arterial disease raises limb-ischemia risk substantially • VV-ECMO requires adequate central venous access for two large-bore venous cannulas without excessive recirculation risk
The assessment stage is iterative: patients can transition from VV to VA (if cardiac function deteriorates on ECMO) or, less commonly, be de-escalated from VA to VV as cardiac function recovers while lung injury persists — a scenario directly relevant to the differential hypoxia risk discussed in Stage 4.
In VV-ECMO, deoxygenated blood is drained from a large central vein, pumped through an oxygenator that adds oxygen and removes carbon dioxide, and the oxygenated blood is returned — to another point in the venous system, not to an artery. The circuit is entirely venous-to-venous. The native heart receives this oxygen-enriched blood via the right atrium, pumps it through the native (injured) lungs and out to the body exactly as it always has. VV-ECMO corrects blood gas content; it does not touch perfusion pressure or cardiac output.
The defining feature of VV-ECMO is that both limbs of the circuit sit in the venous circulation:
Drainage cannula: typically placed in the femoral vein, with the tip advanced to the inferior vena cava (IVC)/right atrial junction. Deoxygenated, CO2-rich blood is drawn out here.
Return cannula: placed in the internal jugular vein (IJ), with the tip positioned in the right atrium, directing the oxygenated return stream across the tricuspid valve. Alternatively, a single dual-lumen catheter (e.g., a bicaval dual-lumen cannula placed via the right IJ) can perform both drainage and return through one venipuncture, with the return jet aimed directly at the tricuspid valve to minimize recirculation.
Blood path: femoral vein → drainage cannula → centrifugal pump → membrane oxygenator (O2 added, CO2 removed) → return cannula → right atrium → right ventricle → native pulmonary circulation → left heart → systemic circulation.
Because the return blood re-enters the venous side and must still pass through the right heart, native lungs, and left heart to reach the body, VV-ECMO never bypasses the heart — the heart remains the sole driver of forward flow throughout the run.
VV-ECMO does not increase blood pressure, cardiac output, or coronary/cerebral perfusion. A patient in VV-ECMO with a failing heart will not be hemodynamically rescued by the circuit — this is precisely why correct triage at Stage 1 matters.
Because drainage and return cannulas both sit in the same venous compartment, some freshly oxygenated blood exiting the return cannula can be immediately pulled back into the nearby drainage cannula before it ever reaches the right ventricle — a phenomenon called recirculation.
Recirculation reduces the effective oxygen delivery of the circuit: the oxygenator is "re-treating" blood that never delivered its oxygen to the patient, rather than treating fresh venous return from the body.
Factors that increase recirculation: • Drainage and return cannula tips positioned too close together • High pump blood flow relative to patient cardiac output • Elevated right atrial pressure
Mitigation strategies: • Maximizing physical separation between cannula tips (e.g., femoral drainage + IJ return, tips ideally >10 cm apart) • Dual-lumen single-cannula designs with an internal return jet engineered to aim across the tricuspid valve, away from the drainage ports • Monitoring pre-oxygenator (venous) saturation — a rising pre-membrane SvO2 despite unchanged patient status is the classic sign of increasing recirculation
Provides: • Full or near-full replacement of gas exchange (oxygenation and CO2 removal) independent of native lung function • Allows "ultra-lung-protective" ventilator settings (low tidal volume, lower plateau pressure, reduced FiO2) to minimize ventilator-induced lung injury while the lungs recover • Preserves pulsatile, physiologic arterial flow because the native heart remains the only pump feeding the arterial tree
Does NOT provide: • Any direct hemodynamic/circulatory support — if the heart fails, VV-ECMO cannot compensate • Protection against arrhythmia-related hemodynamic collapse • Correction of right ventricular failure caused by severe pulmonary hypertension, beyond the indirect benefit of improved oxygenation reducing hypoxic pulmonary vasoconstriction
Because of this, ongoing hemodynamic monitoring is still essential during VV-ECMO — deteriorating cardiac function during the run is one of the main reasons a patient may need conversion to VA-ECMO or a hybrid configuration.
VA-ECMO drains venous blood exactly as VV-ECMO does, but returns the oxygenated blood into the arterial system instead — most commonly the femoral artery, or directly into the aorta in central cannulation. This single change in the return site transforms the circuit from a gas-exchange device into a partial or complete cardiac-and-pulmonary bypass system: the pump itself now generates forward flow and perfusion pressure, in parallel with (or largely replacing) the native heart.
VA-ECMO shares the venous drainage limb with VV-ECMO but diverges entirely at the return side:
Drainage cannula: femoral vein (or, in central cannulation via sternotomy, directly from the right atrium), advanced toward the IVC/right atrial junction, draining deoxygenated blood exactly as in VV-ECMO.
Return cannula: placed in the femoral artery (peripheral VA-ECMO) with the tip typically directed toward the iliac artery/aorta, or sewn directly into the ascending aorta (central VA-ECMO, most often used in post-cardiotomy shock). Oxygenated blood is pumped under pressure into the arterial tree.
Blood path (peripheral VA-ECMO): femoral vein → drainage cannula → centrifugal pump → membrane oxygenator → return cannula → femoral artery → retrograde flow up the iliac artery and aorta → systemic circulation, meeting antegrade flow from the native heart somewhere along the aorta (the "mixing point" or "watershed").
Because oxygenated, pressurized blood re-enters the arterial system directly, the ECMO circuit now functions in parallel with the native heart — sharing, or in severe cardiogenic shock almost entirely assuming, the job of generating cardiac output and mean arterial pressure.
VA-ECMO bypasses both the heart and the lungs: blood can complete a full circuit — venous drainage, oxygenation, and arterial return — without ever passing through the native right heart, pulmonary circulation, or left heart. This is what makes it capable of supporting a patient in complete cardiac arrest.
Peripheral VA-ECMO: • Cannulas placed percutaneously or via surgical cutdown into femoral vessels (occasionally axillary artery for return) • Faster to initiate, does not require sternotomy — preferred for emergent cannulation including ECPR • Retrograde arterial flow direction creates the differential hypoxia risk discussed in Stage 4 • Requires a distal limb perfusion catheter in most cases to prevent limb ischemia
Central VA-ECMO: • Cannulas placed directly into the right atrium (drainage) and ascending aorta (return) via open sternotomy • Used primarily for post-cardiotomy shock when the chest is already open, or when peripheral vessels are inadequate • Antegrade aortic return flow avoids the retrograde-flow mixing-point physiology seen in peripheral configuration • Higher risk of mediastinal bleeding and infection; typically requires a more controlled ICU/OR environment for cannulation and decannulation
Returning oxygenated blood retrograde into the arterial tree has physiological consequences beyond simple flow augmentation:
Increased LV afterload: peripheral VA-ECMO return flow opposes the direction of native antegrade aortic flow, raising left ventricular afterload. In a already-weak left ventricle, this can worsen LV distension, raise LV end-diastolic pressure, and promote pulmonary edema — a phenomenon requiring vigilant monitoring (and sometimes an LV "vent" or Impella device to unload the ventricle).
Competitive flow / mixing point: with peripheral cannulation, retrograde ECMO flow from the femoral artery meets native antegrade flow from the heart somewhere in the aorta. The location of this mixing point shifts depending on the relative strength of native cardiac output versus ECMO flow — and determines which blood (native, poorly oxygenated, versus ECMO-oxygenated) perfuses the upper body, setting up the differential hypoxia risk.
Weaning physiology: because VA-ECMO directly substitutes for cardiac output, weaning requires demonstrating that the native heart can sustain adequate perfusion pressure and flow as pump support is progressively reduced — assessed via echocardiography and hemodynamic trends during flow-reduction trials.
VV- and VA-ECMO diverge not only in what they treat but in what they risk. VA-ECMO's arterial cannulation introduces mechanical threats to distal limb perfusion that simply do not exist in a venous-only circuit. VV-ECMO avoids those mechanical risks entirely — but because it provides no hemodynamic support, it cannot compensate if cardiac function deteriorates. And VA-ECMO carries its own unique physiological hazard when the native heart starts to recover while the lungs remain injured: differential hypoxia, or "Harlequin syndrome."
Placing a large-bore return cannula in the femoral artery partially or completely obstructs antegrade blood flow to the leg distal to the cannulation site, since the cannula itself occupies a significant fraction of the vessel lumen.
Mechanism: • The arterial cannula (commonly 15–19 Fr) can occlude enough of the femoral artery cross-section to critically reduce distal limb perfusion, especially in smaller or diseased vessels • Ischemia may present as pallor, coolness, diminished or absent distal pulses, worsening pain, and — if unrecognized — compartment syndrome or limb loss
Prevention and mitigation: • Distal limb perfusion catheter ("backflow" or "reperfusion" cannula): a smaller catheter placed antegrade into the superficial femoral artery, connected to the arterial limb of the circuit, restoring some forward flow to the leg despite the occluding main cannula — now considered standard of care at most centers using femoral arterial return • Routine near-infrared spectroscopy (NIRS) or serial vascular exams of the cannulated limb • Vessel size matching (ultrasound-guided cannula sizing) before cannulation
This is a purely mechanical, site-specific risk with no VV-ECMO equivalent, because VV-ECMO never places a cannula in an artery.
Limb ischemia is essentially eliminated as a possibility in VV-ECMO because both cannulas sit in low-pressure veins with abundant collateral venous drainage — there is no artery being obstructed. This is one of VV-ECMO's clearest safety advantages when the indication genuinely calls for gas-exchange-only support.
Differential hypoxia arises specifically in peripheral VA-ECMO when native cardiac function partially recovers while the native lungs remain severely injured.
Mechanism: • In peripheral VA-ECMO, oxygenated ECMO blood enters retrograde from the femoral artery and perfuses the lower body and abdominal organs well • As the native heart recovers contractility, it begins ejecting more of its own blood antegrade up the ascending aorta — blood that has passed through the still-injured native lungs and is therefore poorly oxygenated • A "mixing point" forms in the aorta (often near the aortic arch) between well-oxygenated retrograde ECMO flow and poorly-oxygenated antegrade native flow • If native cardiac output is strong enough, the poorly-oxygenated native blood can dominate perfusion of the upper body — including the coronary arteries and the brain — while the lower body continues to receive well-oxygenated ECMO blood
Clinical recognition — the "Harlequin" pattern: • Named for the two-toned harlequin costume: the upper body (head, right arm, coronary circulation) may appear cyanotic/dusky while the lower body remains pink • Detected by simultaneous pulse oximetry monitoring on the right hand/ear (reflecting the aortic arch/cerebral circulation) versus a lower-body site • A right-hand SpO2 significantly lower than a lower-limb SpO2 is the classic diagnostic clue
Management: • Increase FiO2/ventilator support to improve native lung oxygenation of the antegrade stream • Consider converting to central cannulation, or adding a return cannula further upstream (veno-arterial-venous, VAV, hybrid configuration) to ensure oxygenated blood reaches the coronary and cerebral circulation • This complication has no VV-ECMO equivalent, because VV-ECMO relies entirely on the native heart to distribute a single, uniformly oxygenated blood pool — there is no competing retrograde arterial stream to create a mixing point.
The complication profiles of VV- and VA-ECMO are close to mirror images of each other:
VA-ECMO trades hemodynamic support for mechanical and physiological arterial risk: limb ischemia from the cannula itself, and differential hypoxia from the retrograde-flow mixing-point physiology as cardiac recovery outpaces respiratory recovery.
VV-ECMO trades away hemodynamic support to avoid those arterial risks entirely: no limb ischemia, no Harlequin physiology — but also zero buffer if the heart fails during the run.
This is why Stage 1's indication assessment is so consequential: choosing VA-ECMO for a patient who only needed gas-exchange support exposes them to arterial complications they did not need to risk, while choosing VV-ECMO for a patient with significant cardiac dysfunction leaves that dysfunction completely unsupported.
The final step folds every prior stage together: the primary indication (is the failure respiratory, cardiac, or both?), the physiological consequences of each circuit design, and the configuration-specific complication profile, into one actionable recommendation. This is also a living decision — patients can be re-triaged mid-run as cardiac or respiratory status evolves, and hybrid configurations exist for the minority of cases that do not fit cleanly into either category.
Combining the two axes assessed in Stage 1 yields a practical decision rule:
Cardiac function preserved (adequate cardiac index, MAP maintained without escalating vasopressors) + respiratory failure is the dominant problem → VV-ECMO. The heart does not need replacing; only gas exchange does. Choosing VA here would add arterial cannulation risk (limb ischemia, potential differential hypoxia) with no compensating benefit.
Cardiac function impaired (low cardiac index, refractory hypotension/shock, cardiac arrest) — regardless of how severe the respiratory failure also is → VA-ECMO. Only an arterial-return circuit can generate the perfusion pressure and flow the failing heart cannot. This holds true even when respiratory failure is severe, because VV-ECMO simply has no mechanism to support blood pressure or cardiac output.
The cardiac axis dominates the decision: any significant degree of cardiogenic shock overrides respiratory severity in determining the need for arterial return, because only VA-ECMO can substitute for a failing pump.
A concise rule of thumb used across ECMO programs: "If the lungs are failing and the heart is fine, go VV. If the heart is failing — with or without lung failure — go VA." The sliders in this simulator implement exactly this rule.
The initial choice is not necessarily permanent. ECMO configuration should be reassessed whenever the patient's trajectory diverges from the original indication:
VV → VA conversion: a patient started on VV-ECMO for isolated ARDS may develop new cardiogenic shock (e.g., sepsis-induced cardiomyopathy, arrhythmia, myocardial infarction) — an arterial return cannula can be added to convert to a veno-arterial-venous (VAV) or full VA configuration.
VA → VV conversion (or VA decannulation with continued VV support): a patient started on VA-ECMO for combined cardiogenic and respiratory failure may recover cardiac function while lung injury persists — at this point, continuing arterial cannulation only adds limb-ischemia and differential-hypoxia risk without added benefit, so the arterial limb can potentially be removed while venous-only support continues if gas exchange support is still needed.
Hybrid VAV-ECMO: used when a patient needs both substantial hemodynamic support AND is at risk of differential hypoxia — a third cannula (typically venous return, in addition to the arterial return) delivers oxygenated blood to the right heart to ensure the upper body/coronary circulation receives adequately oxygenated blood even if native lung function is poor.
Before finalizing cannulation configuration, a structured recommendation should confirm:
1. Indication confirmed: is the dominant physiological problem gas exchange, perfusion, or both — supported by objective hemodynamic and respiratory data, not gestalt alone 2. Cardiac function quantified: recent echocardiogram, cardiac index/output if available, current vasopressor/inotrope requirement 3. Respiratory severity quantified: PaO2/FiO2 ratio, compliance, ventilator settings already optimized 4. Vascular access assessed: for VA candidates, peripheral arterial anatomy evaluated for cannula sizing and distal perfusion catheter planning 5. Risk-benefit explicitly weighed: does the marginal hemodynamic benefit of VA justify the added arterial risk, or does the patient's cardiac reserve make VV sufficient 6. Reassessment plan in place: explicit triggers defined for escalation (VV→VA) or de-escalation (VA→VV) as the clinical picture evolves
The configuration decision is the foundation of the entire ECMO run — it determines cannula sites, expected complications, monitoring strategy, and the pathway to eventual weaning and decannulation.